高中生高血压 (HYGEF)
高中生高血压:遗传和环境因素
研究概览
详细说明
小儿高血压与心血管器官损伤有关,进而可能导致成年后发生心血管疾病 (CVD) 和急性事件。1 在过去的几十年中,儿童和青少年的高血压患病率逐渐增加,产生了重大的公共卫生问题和大量的研究。 与成人相比,青少年血压值的异质性较小,遗传因素的影响即使很小,也可能是自出生以来就存在的致病机制的表达。
通过这项名为 HYGEF(高中生高血压:遗传和环境因素)的研究,作者希望:1. 确定青少年群体中肥胖和高血压 (HT) 的患病率,2. 进行遗传分析以确定两者之间的联系3. 探讨与成人 HT 发展相关的基因的特定多态性和/或突变之间的关系,例如内收蛋白基因和内源性哇巴因 (EO) 与 HT 之间的关系,以及 3. 探讨尿液 Na+/K+ 排泄以及尿液炎症和氧化应激标志物是否与具有选定基因型的参与者的HT和心血管风险。
青少年将在意大利北部(米兰)、中部(利沃诺)和南部(格罗塔列)的高中报名参加研究,以获得可以代表意大利青少年的样本。 在访问高中期间,调查人员获取了一些调查问卷,以了解有关饮食习惯、生活方式和家族史的一些信息、两个(或三个非常不一致的)血压测量值、学生的体重和身高、尿液样本和唾液样本以提取 DNA。
基因分型:在我们前期对成年高血压及心血管和肾脏相关疾病患者进行的遗传学研究的基础上,筛选出位于13个候选基因的15个SNP:ABCB1中的rs1045642、ACE(血管紧张素转换酶)中的rs4343、 ADD1(α-内收蛋白)、ADD2(β-内收蛋白)中的 rs4984、ADD3(γ-内收蛋白)中的 rs3731566、CYP11A1(细胞色素 P450 家族 11 亚家族 A 成员 1)中的 rs11638442、CYP11B2(醛固酮合酶)中的 rs1799998、rs2236780 ,RS6203 HSD3B1 遗传区中的 rs10923835、KL 中的 rs9536314、LSS 中的 rs2254524、神经前体细胞中表达的 rs4149601、发育下调的 4-like、NEDD4L(E3 泛素蛋白连接酶)、PRKG1(蛋白激酶、cGMP 依赖性中的 rs1904694, I 型),UMOD(尿调节素)中的 rs4238595。
尿液分析:在第一个空腹晨尿样本中测量 Na+、K+、白蛋白和肌酐。 川崎公式用于估计 24 小时尿钠 (24h UNa) 排泄量,表示为 mEq/24 h。 在小组中,每个学生的尿斑样本将立即冷冻以进行蛋白质分析。 研究人员计划使用 LXSAHM Human Magnetic Luminex Screening Assay 通过 ELISA 测试同时测量 IL1β、IL6、IL10、IL12p70、TNF-α、MCP1(单核细胞趋化蛋白)、PTX3 (pentraxin-3)。 可溶性 α-Klotho、8-Oxo-2'-脱氧鸟苷将通过 Elisa 试剂盒测定进行测量。 一氧化氮 (NO) 通过比色一氧化氮测定试剂盒测量。 高级氧化蛋白产品将使用比色 OxiSelect 高级氧化蛋白产品检测试剂盒进行测量。
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
-
Milan、意大利、20132
- IRCCS Ospedale San Raffaele
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
接受健康志愿者
取样方法
研究人群
描述
纳入标准:
- 年龄在13岁至19岁之间
- 白种人
排除标准:
- 年龄超过19岁
- 不是白人
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
---|
13至15岁
|
16至19岁
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
该研究的目的是建立内收蛋白和 EO 相关基因的特定多态性与选定表型(高血压、Na+ 和 K+ 摄入量)之间的联系。
大体时间:2年
|
2年
|
合作者和调查者
出版物和有用的链接
一般刊物
- National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004 Aug;114(2 Suppl 4th Report):555-76. No abstract available.
- Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER 3rd, Simons-Morton DG, Karanja N, Lin PH; DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001 Jan 4;344(1):3-10. doi: 10.1056/NEJM200101043440101.
- Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007 Sep;81(3):559-75. doi: 10.1086/519795. Epub 2007 Jul 25.
- Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ, Sacks FM; American Heart Association. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension. 2006 Feb;47(2):296-308. doi: 10.1161/01.HYP.0000202568.01167.B6.
- Staessen JA, Wang JG, Brand E, Barlassina C, Birkenhager WH, Herrmann SM, Fagard R, Tizzoni L, Bianchi G. Effects of three candidate genes on prevalence and incidence of hypertension in a Caucasian population. J Hypertens. 2001 Aug;19(8):1349-58. doi: 10.1097/00004872-200108000-00002. Erratum In: J Hypertens 2001 Oct;19(10):1921.
- Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. Intersalt Cooperative Research Group. BMJ. 1988 Jul 30;297(6644):319-28. doi: 10.1136/bmj.297.6644.319.
- Polonia J, Lobo MF, Martins L, Pinto F, Nazare J. Estimation of populational 24-h urinary sodium and potassium excretion from spot urine samples: evaluation of four formulas in a large national representative population. J Hypertens. 2017 Mar;35(3):477-486. doi: 10.1097/HJH.0000000000001180.
- Tripodi G, Citterio L, Kouznetsova T, Lanzani C, Florio M, Modica R, Messaggio E, Hamlyn JM, Zagato L, Bianchi G, Staessen JA, Manunta P. Steroid biosynthesis and renal excretion in human essential hypertension: association with blood pressure and endogenous ouabain. Am J Hypertens. 2009 Apr;22(4):357-63. doi: 10.1038/ajh.2009.3. Epub 2009 Feb 5.
- Citterio L, Lanzani C, Manunta P, Bianchi G. Genetics of primary hypertension: the clinical impact of adducin polymorphisms. Biochim Biophys Acta. 2010 Dec;1802(12):1285-98. doi: 10.1016/j.bbadis.2010.03.014. Epub 2010 Apr 8.
- Liu M, Li Y, Citterio L, Huang QF, Zeng WF, Sheng CS, Wei FF, Dong Q, Li GL, Kang YY, Zhang L, Xu TY, Li JJ, Song J, Manunta P, Wang JG. A functional common polymorphism of the ABCB1 gene is associated with chronic kidney disease and hypertension in Chinese. Am J Hypertens. 2013 Dec;26(12):1428-36. doi: 10.1093/ajh/hpt126. Epub 2013 Aug 7.
- de Simone G, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol. 1995 Apr;25(5):1056-62. doi: 10.1016/0735-1097(94)00540-7.
- Lurbe E, Agabiti-Rosei E, Cruickshank JK, Dominiczak A, Erdine S, Hirth A, Invitti C, Litwin M, Mancia G, Pall D, Rascher W, Redon J, Schaefer F, Seeman T, Sinha M, Stabouli S, Webb NJ, Wuhl E, Zanchetti A. 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens. 2016 Oct;34(10):1887-920. doi: 10.1097/HJH.0000000000001039.
- Efendiev R, Krmar RT, Ogimoto G, Zwiller J, Tripodi G, Katz AI, Bianchi G, Pedemonte CH, Bertorello AM. Hypertension-linked mutation in the adducin alpha-subunit leads to higher AP2-mu2 phosphorylation and impaired Na+,K+-ATPase trafficking in response to GPCR signals and intracellular sodium. Circ Res. 2004 Nov 26;95(11):1100-8. doi: 10.1161/01.RES.0000149570.20845.89. Epub 2004 Nov 4.
- Manunta P, Maillard M, Tantardini C, Simonini M, Lanzani C, Citterio L, Stella P, Casamassima N, Burnier M, Hamlyn JM, Bianchi G. Relationships among endogenous ouabain, alpha-adducin polymorphisms and renal sodium handling in primary hypertension. J Hypertens. 2008 May;26(5):914-20. doi: 10.1097/HJH.0b013e3282f5315f.
- Ferrari P. Rostafuroxin: an ouabain-inhibitor counteracting specific forms of hypertension. Biochim Biophys Acta. 2010 Dec;1802(12):1254-8. doi: 10.1016/j.bbadis.2010.01.009. Epub 2010 Jan 18.
- Blaustein MP, Chen L, Hamlyn JM, Leenen FH, Lingrel JB, Wier WG, Zhang J. Pivotal role of alpha2 Na+ pumps and their high affinity ouabain binding site in cardiovascular health and disease. J Physiol. 2016 Nov 1;594(21):6079-6103. doi: 10.1113/JP272419. Epub 2016 Jul 31.
- Manunta P, Iacoviello M, Forleo C, Messaggio E, Hamlyn JM, Lucarelli K, Guida P, Romito R, De Tommasi E, Bianchi G, Rizzon P, Pitzalis MV. High circulating levels of endogenous ouabain in the offspring of hypertensive and normotensive individuals. J Hypertens. 2005 Sep;23(9):1677-81. doi: 10.1097/01.hjh.0000177049.38417.67.
- Nzietchueng R, El Shamieh S, Benachour H, Labat C, Herbeth B, Ndiaye NC, Masson C, Visvikis-Siest S, Benetos A. Klotho KL-VS genotype is involved in blood pressure regulation. Clin Chim Acta. 2011 Sep 18;412(19-20):1773-7. doi: 10.1016/j.cca.2011.05.032. Epub 2011 Jun 1.
- Zhou X, Chen K, Lei H, Sun Z. Klotho gene deficiency causes salt-sensitive hypertension via monocyte chemotactic protein-1/CC chemokine receptor 2-mediated inflammation. J Am Soc Nephrol. 2015 Jan;26(1):121-32. doi: 10.1681/ASN.2013101033. Epub 2014 Jun 5.
- Manunta P, Lavery G, Lanzani C, Braund PS, Simonini M, Bodycote C, Zagato L, Delli Carpini S, Tantardini C, Brioni E, Bianchi G, Samani NJ. Physiological interaction between alpha-adducin and WNK1-NEDD4L pathways on sodium-related blood pressure regulation. Hypertension. 2008 Aug;52(2):366-72. doi: 10.1161/HYPERTENSIONAHA.108.113977. Epub 2008 Jun 30.
- Citterio L, Simonini M, Zagato L, Salvi E, Delli Carpini S, Lanzani C, Messaggio E, Casamassima N, Frau F, D'Avila F, Cusi D, Barlassina C, Manunta P. Genes involved in vasoconstriction and vasodilation system affect salt-sensitive hypertension. PLoS One. 2011 May 9;6(5):e19620. doi: 10.1371/journal.pone.0019620.
- Trudu M, Janas S, Lanzani C, Debaix H, Schaeffer C, Ikehata M, Citterio L, Demaretz S, Trevisani F, Ristagno G, Glaudemans B, Laghmani K, Dell'Antonio G; SKIPOGH team; Loffing J, Rastaldi MP, Manunta P, Devuyst O, Rampoldi L. Common noncoding UMOD gene variants induce salt-sensitive hypertension and kidney damage by increasing uromodulin expression. Nat Med. 2013 Dec;19(12):1655-60. doi: 10.1038/nm.3384. Epub 2013 Nov 3.
- Kuznetsova T, Staessen JA, Thijs L, Kunath C, Olszanecka A, Ryabikov A, Tikhonoff V, Stolarz K, Bianchi G, Casiglia E, Fagard R, Brand-Herrmann SM, Kawecka-Jaszcz K, Malyutina S, Nikitin Y, Brand E; European Project On Genes in Hypertension (EPOGH) Investigators. Left ventricular mass in relation to genetic variation in angiotensin II receptors, renin system genes, and sodium excretion. Circulation. 2004 Oct 26;110(17):2644-50. doi: 10.1161/01.CIR.0000145541.63406.BA. Epub 2004 Oct 18.
- Munshi A, Sharma V, Kaul S, Rajeshwar K, Babu MS, Shafi G, Anila AN, Balakrishna N, Alladi S, Jyothy A. Association of the -344C/T aldosterone synthase (CYP11B2) gene variant with hypertension and stroke. J Neurol Sci. 2010 Sep 15;296(1-2):34-8. doi: 10.1016/j.jns.2010.06.013. Epub 2010 Jul 3. Erratum In: J Neurol Sci. 2012 Oct 15;321(1-2):122.
- Tanase DM, Gosav EM, Radu S, Ouatu A, Rezus C, Ciocoiu M, Costea CF, Floria M. Arterial Hypertension and Interleukins: Potential Therapeutic Target or Future Diagnostic Marker? Int J Hypertens. 2019 May 2;2019:3159283. doi: 10.1155/2019/3159283. eCollection 2019.
- Li Y, Thijs L, Kuznetsova T, Zagato L, Struijker-Boudier H, Bianchi G, Staessen JA. Cardiovascular risk in relation to alpha-adducin Gly460Trp polymorphism and systolic pressure: a prospective population study. Hypertension. 2005 Sep;46(3):527-32. doi: 10.1161/01.HYP.0000174988.81829.72. Epub 2005 Jul 25.
- Manunta P, Ferrandi M, Cusi D, Ferrari P, Staessen J, Bianchi G. Personalized Therapy of Hypertension: the Past and the Future. Curr Hypertens Rep. 2016 Mar;18(3):24. doi: 10.1007/s11906-016-0632-y.
- Seidlerova J, Staessen JA, Bochud M, Nawrot T, Casamassima N, Citterio L, Kuznetsova T, Jin Y, Manunta P, Richart T, Struijker-Boudier HA, Fagard R, Filipovsky J, Bianchi G. Arterial properties in relation to genetic variations in the adducin subunits in a white population. Am J Hypertens. 2009 Jan;22(1):21-6. doi: 10.1038/ajh.2008.261. Epub 2008 Sep 11.
- Iatrino R, Lanzani C, Bignami E, Casamassima N, Citterio L, Meroni R, Zagato L, Zangrillo A, Alfieri O, Fontana S, Macrina L, Delli Carpini S, Messaggio E, Brioni E, Dell'Antonio G, Manunta P, Hamlyn JM, Simonini M. Lanosterol Synthase Genetic Variants, Endogenous Ouabain, and Both Acute and Chronic Kidney Injury. Am J Kidney Dis. 2019 Apr;73(4):504-512. doi: 10.1053/j.ajkd.2018.10.012. Epub 2019 Jan 16.
- Citterio L, Ferrandi M, Delli Carpini S, Simonini M, Kuznetsova T, Molinari I, Dell' Antonio G, Lanzani C, Merlino L, Brioni E, Staessen JA, Bianchi G, Manunta P. cGMP-dependent protein kinase 1 polymorphisms underlie renal sodium handling impairment. Hypertension. 2013 Dec;62(6):1027-33. doi: 10.1161/HYPERTENSIONAHA.113.01628. Epub 2013 Sep 23.
- Kawasaki T, Itoh K, Uezono K, Sasaki H. A simple method for estimating 24 h urinary sodium and potassium excretion from second morning voiding urine specimen in adults. Clin Exp Pharmacol Physiol. 1993 Jan;20(1):7-14. doi: 10.1111/j.1440-1681.1993.tb01496.x. Erratum In: Clin Exp Pharmacol Physiol 1993 Mar;20(3):199.
- Cappuccio FP, Ji C, Donfrancesco C, Palmieri L, Ippolito R, Vanuzzo D, Giampaoli S, Strazzullo P. Geographic and socioeconomic variation of sodium and potassium intake in Italy: results from the MINISAL-GIRCSI programme. BMJ Open. 2015 Sep 10;5(9):e007467. doi: 10.1136/bmjopen-2014-007467.
- Welsh CE, Welsh P, Jhund P, Delles C, Celis-Morales C, Lewsey JD, Gray S, Lyall D, Iliodromiti S, Gill JMR, Sattar N, Mark PB. Urinary Sodium Excretion, Blood Pressure, and Risk of Future Cardiovascular Disease and Mortality in Subjects Without Prior Cardiovascular Disease. Hypertension. 2019 Jun;73(6):1202-1209. doi: 10.1161/HYPERTENSIONAHA.119.12726.
- Andrukhova O, Slavic S, Smorodchenko A, Zeitz U, Shalhoub V, Lanske B, Pohl EE, Erben RG. FGF23 regulates renal sodium handling and blood pressure. EMBO Mol Med. 2014 Jun;6(6):744-59. doi: 10.1002/emmm.201303716. Epub 2014 Apr 6.
- Cusi D, Barlassina C, Azzani T, Casari G, Citterio L, Devoto M, Glorioso N, Lanzani C, Manunta P, Righetti M, Rivera R, Stella P, Troffa C, Zagato L, Bianchi G. Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet. 1997 May 10;349(9062):1353-7. doi: 10.1016/S0140-6736(97)01029-5. Erratum In: Lancet 1997 Aug 16;350(9076):524.
- Taylor WR. Hypertensive vascular disease and inflammation: mechanical and humoral mechanisms. Curr Hypertens Rep. 1999 Feb-Mar;1(1):96-101. doi: 10.1007/s11906-999-0079-5.
- Libby P. Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond. J Am Coll Cardiol. 2017 Oct 31;70(18):2278-2289. doi: 10.1016/j.jacc.2017.09.028.
- Li QZ, Deng Q, Li JQ, Yi GH, Zhao SP. Valsartan reduces interleukin-1beta secretion by peripheral blood mononuclear cells in patients with essential hypertension. Clin Chim Acta. 2005 May;355(1-2):131-6. doi: 10.1016/j.cccn.2004.12.006.
- Elijovich F, Weinberger MH, Anderson CA, Appel LJ, Bursztyn M, Cook NR, Dart RA, Newton-Cheh CH, Sacks FM, Laffer CL; American Heart Association Professional and Public Education Committee of the Council on Hypertension; Council on Functional Genomics and Translational Biology; and Stroke Council. Salt Sensitivity of Blood Pressure: A Scientific Statement From the American Heart Association. Hypertension. 2016 Sep;68(3):e7-e46. doi: 10.1161/HYP.0000000000000047. Epub 2016 Jul 21. No abstract available. Erratum In: Hypertension. 2016 Oct;68(4):e62.
- Lin RC, Morris BJ. Association analysis of polymorphisms at the interleukin-1 locus in essential hypertension. Am J Med Genet. 2002 Feb 1;107(4):311-6. doi: 10.1002/ajmg.10177.
- Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010 Mar;10(3):170-81. doi: 10.1038/nri2711. Epub 2010 Feb 15.
- Caligiuri G, Rudling M, Ollivier V, Jacob MP, Michel JB, Hansson GK, Nicoletti A. Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice. Mol Med. 2003 Jan-Feb;9(1-2):10-7.
- Lima VV, Zemse SM, Chiao CW, Bomfim GF, Tostes RC, Clinton Webb R, Giachini FR. Interleukin-10 limits increased blood pressure and vascular RhoA/Rho-kinase signaling in angiotensin II-infused mice. Life Sci. 2016 Jan 15;145:137-43. doi: 10.1016/j.lfs.2015.12.009. Epub 2015 Dec 9.
- Chatterjee P, Chiasson VL, Seerangan G, Tobin RP, Kopriva SE, Newell-Rogers MK, Mitchell BM. Cotreatment with interleukin 4 and interleukin 10 modulates immune cells and prevents hypertension in pregnant mice. Am J Hypertens. 2015 Jan;28(1):135-42. doi: 10.1093/ajh/hpu100. Epub 2014 Jun 6.
- van den Hoogen PC, Feskens EJ, Nagelkerke NJ, Menotti A, Nissinen A, Kromhout D. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N Engl J Med. 2000 Jan 6;342(1):1-8. doi: 10.1056/NEJM200001063420101.
- Jin Y, Kuznetsova T, Citterio L, Thijs L, Messaggio E, Casamassima N, Manunta P, Fagard R, Bianchi G, Staessen JA. Left ventricular structure and function in relation to steroid biosynthesis genes in a white population. Am J Hypertens. 2012 Sep;25(9):986-93. doi: 10.1038/ajh.2012.69. Epub 2012 Jun 7.
- Tentori S, Messaggio E, Brioni E, Casamassima N, Simonini M, Zagato L, Hamlyn JM, Manunta P, Lanzani C. Endogenous ouabain and aldosterone are coelevated in the circulation of patients with essential hypertension. J Hypertens. 2016 Oct;34(10):2074-80. doi: 10.1097/HJH.0000000000001042.
- Cooper RS, Zhu X. Racial differences and the genetics of hypertension. Curr Hypertens Rep. 2001 Feb;3(1):19-24. doi: 10.1007/s11906-001-0073-z.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.